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Genotype-outcome correlations in pediatric AML: the impact
of a monosomal karyotype in trial AML-BFM 2004
M Rasche1, C von Neuhoff1, M Dworzak2, J-P Bourquin3, J Bradtke4, G Göhring5, G Escherich6, G Fleischhack1, N Graf7, B Gruhn8,
OA Haas9, T Klingebiel10, B Kremens1, T Lehrnbecher10, A von Stackelberg11, J Tchinda3, Z Zemanova12, C Thiede13, N von Neuhoff1,
M Zimmermann14, U Creutzig14 and D Reinhardt1
We conducted a cytogenetic analysis of 642 children with de novo acute myeloid leukemia (AML) treated on the AML-Berlin-
Frankfurt-Münster (BFM) 04 protocol to determine the prognostic value of speciﬁc chromosomal aberrations including monosomal
(MK+), complex (CK+) and hypodiploid (HK+) karyotypes, individually and in combination. Multivariate regression analysis identiﬁed
in particular MK+ (n= 22) as a new independent risk factor for poor event-free survival (EFS 23 ± 9% vs 53 ± 2% for all other patients,
P= 0.0003), even after exclusion of four patients with monosomy 7 (EFS 28± 11%, P= 0.0081). CK+ patients without MK had a better
prognosis (n= 47, EFS 47 ± 8%, P= 0.46) than those with MK+ (n= 12, EFS 25 ± 13%, P= 0.024). HK+ (n= 37, EFS 44 ± 8% for total
cohort, P= 0.3) inﬂuenced outcome only when t(8;21) patients were excluded (remaining n= 16, EFS 9 ± 8%, Po0.0001). An
extremely poor outcome was observed for MK+/HK+ patients (n= 10, EFS 10 ± 10%, Po0.0001). Finally, isolated trisomy 8 was also
associated with low EFS (n= 16, EFS 25 ± 11%, P= 0.0091). In conclusion, monosomal karyotype is a strong and independent
predictor for high-risk pediatric AML. In addition, isolated trisomy 8 and hypodiploidy without t(8;21) coincide with dismal outcome.
These results have important implications for risk stratiﬁcation and should be further validated in independent pediatric cohorts.
Leukemia (2017) 31, 2807–2814; doi:10.1038/leu.2017.121
INTRODUCTION
In recent years, analyses of molecular and cytogenetic aberrations
have revealed the heterogeneity of pediatric acute myeloid
leukemia (AML),1,2 which is now partially incorporated within the
World Health Organization classiﬁcation and current risk stratiﬁca-
tion systems.3–5 To date, most study groups have agreed on
favorable prognostic factors such as inv(16)(p13.1q22)/CBFB-
MYH11, or t(16;16)(p13.1;q22), t(8;21)(q22;q22)/RUNX1-RUNX1T1,
t(15;17)/PML-RARA, single NPM1 mutations or double mutated
CEBPA.1,2,4–6 However, conﬂicting data on risk factors for poor
outcomes represent the highly variable deﬁnitions of high-risk
AML among international study groups and reﬂect the urgent
need to analyze potentially high-risk aberrations in large pediatric
cohorts.
Monosomy 7 is a well-described unfavorable prognostic factor
in pediatric and adult patients with AML.2,7 In adult AML, a deﬁned
group of patients harboring a monosomal karyotype (MK) has
been found to experience exceedingly poor outcomes.8–13
However, in children, the predictive relevance of a MK remains
unclear.14 A recent study elucidated the impact of modal numbers
in pediatric AML, assuming that a hypodiploid karyotype (HK) may
be related to poor outcome.15 For complex karyotype (CK),
however, varying deﬁnitions exist and patients are treated
heterogeneously. Even with differences in karyotype deﬁnitions,
current collaborative studies mostly recommend allogeneic stem
cell transplantation (HSCT) during the ﬁrst complete remission
(1st CR) for treatment of genetically deﬁned high-risk patients.16
Thus, it is crucial to carefully deﬁne high-risk factors.
In this study, we evaluated correlations between genotype and
outcome for deﬁned aberrant karyotypes in a large, uniquely
treated group of children with AML in the AML-Berlin-Frankfurt-
Münster (BFM) 04 study and considered the results within the
context of the increasing complexity of genetic aberrations.
PATIENTS AND METHODS
Patients
Between March 2004 and March 2012, 764 patients 0–18 years of age with
de novo AML in Germany, Austria, Switzerland, and the Czech Republic
(patients with Down Syndrome excluded) were treated according to the
AML-BFM 04 protocol (ClinicalTrials.gov Identiﬁer: NCT00111345). Initial
diagnosis was performed according to the French-American-British (FAB)
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classiﬁcation.17–19 Bone marrow morphology, ﬂow cytometry and cytoge-
netics were centrally reviewed. National ethics committees and institu-
tional review boards approved this study, and patients or guardians
provided written informed consent. The study was performed in
accordance with the Declaration of Helsinki.
Methods
Cytogenetic data were available for 701 patients (92%) and were collected
and centrally reviewed as previously described.2 The descriptions of
karyotypes followed the International System of Human Cytogenetic
Nomenclature.20 For the following analyses, we excluded patients with
t(15;17)/PML-RARA-fusion gene (probability of event-free survival (EFS)
89 ± 4%, n=59) due to their unique biology and treatment.
Cytogenetics, ﬂuorescence in situ hybridization (FISH) and reverse
transcription polymerase chain reaction (RT-PCR) analyses were performed
using standard protocols with initial bone marrow or peripheral blood
samples. After short-term culture for 12–72 h, metaphases of bone marrow
and/or peripheral blood were prepared according to standard procedures.
Fluorescence R-banding was performed as described by Göhring et al.21 In
patients with MLL-rearrangement (mixed-lineage leukemia, also called
KMT2A), t(15;17)(q22;q21), t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;
q22) the molecular genetic aberrations were analyzed to conﬁrm the
cytogenetic data by FISH on interphase nuclei and by RT-PCR.21,22 In few
patients the conﬁrmation of speciﬁc aberrations in cytogenetics was
performed only by FISH or RT-PCR, and patients were added to the
corresponding cytogenetic subgroup. In detail 16% of patients with MLL-
rearrangement, t(15;17) or t(8;21) were conﬁrmed by FISH only, without
additional conﬁrmation by RT-PCR. Seven percent of patients with MLL-
rearrangement have been conﬁrmed by RT-PCR only.
Analysis of the FLT3 gene (FMS-Related Tyrosine Kinase 3; OMIM No:
136351; localization: 13q12) was performed in 475 patients using PCR with
5′ end D4 WellRED dye-labeled reverse primers (Beckman Coulter, Krefeld,
Germany). Samples were diluted in SLS (CEQt SLS, Beckman Coulter)
containing a CEQ 600 size standard mixture (CEQt DNA Size Standard Kit,
Beckman Coulter). The sizes of the resulting fragments were measured by
capillary fragment analysis on a CEQ8000 genetic analysis system
(Beckman Coulter). Wild-type and mutated alleles were assessed as
proposed by Thiede et al.23 PCR products were subsequently sequenced
using the GenomeLab Dye Terminator Cycle Sequencing with Quick Start
Kit (Beckman Coulter).23–30 Detailed protocols and primer sequences are
available on request.
Risk classiﬁcation
Risk stratiﬁcation was performed as described.31 Patients with FAB M1/M2
with Auer rods or FAB M4eo or favorable cytogenetics [t(8;21)/RUNX1-
RUNX1T1 or inv(16) or t(16;16) and/or CBFB/MYH11)] were assigned to the
standard risk group. All other patients as well as standard risk patients with
FLT3-ITD mutations or bone marrow blasts ⩾ 5% on day 15 were assigned
to the high-risk group.
Treatment
Between March 2004 and April 2010, patients were treated according to
the schedule of study AML-BFM 04, as summarized previously.31 Allogeneic
HSCT from matched sibling donors was limited to high-risk patients in 1st
CR, and after a 2006 amendment, allogeneic HSCT was restricted to only
high-risk patients with persistent disease after second induction (bone
marrow blasts 45%).32,33 Thereafter, patients were treated according to
the AML-BFM 04 protocol but not further randomized. All patients received
the liposomal formulation of daunorubicin during induction therapy, and
all high-risk patients received 2-chloro-2-deoxyadenosine as intensiﬁcation
therapy during the cytarabine/idarubicin consolidation. Furthermore only
high-risk patients received high-dose cytarabine and mitoxantrone (HAM)
as second induction. Randomized cranial irradiation was stopped in May
2009.33
Deﬁnitions
The remission criteria were deﬁned according to the Cancer and Leukemia
Group B criteria at the end of intensiﬁcation.34 EFS was calculated as the
time from diagnosis to the ﬁrst event (relapse, death of any cause, failure
to achieve remission or secondary malignancy) or last follow-up. Failure to
achieve remission was considered an event on day 0. Overall survival (OS)
was deﬁned as the time from the date of diagnosis to the date of death
from any cause or last follow-up. Death within 42 days was considered
early death.
Cytogenetic deﬁnitions
MK was deﬁned as either loss of at least two autosomes or one autosome
and at least one structural abnormality excluding marker and ring
chromosomes. Favorable cytogenetics were excluded. This deﬁnition was
previously described by Breems et al.8 and excluded patients with only one
autosomal monosomy combined with a marker chromosome but no
additional aberration. For further analysis, we deﬁned a subgroup of
patients who fulﬁlled the MK+ criteria but had no involvement of
monosomy 7 (referred to as MK+ no − 7). HK was deﬁned as o46
chromosomes. Patients with HK (HK+) were subdivided as those who
fulﬁlled the criteria for both MK and HK (HK+/MK+) or HK+/MK−. CK was
deﬁned as previously described by von Neuhoff et al.2 by three or more
aberrations, including at least one structural aberration, without favorable
genetics and without MLL-rearrangement. Unbalanced translocations were
counted as one abnormality. Patients with CK (CK+) were similarly
separated into subgroups according to whether they also fulﬁlled the
criteria for MK: CK+/MK+ and CK+/MK−. For further analysis, patients were
analyzed regarding the number of aberrations as described by Grimwade
et al.35 Therefore, we referred to the deﬁnition of Grimwade and counted
an unbalanced translocation as two abnormalities, but again excluded
patients with MLL-rearrangement or favorable genetics.35
In addition, we analyzed patients with MK, excluding any presence of a
marker or ring chromosome and patients with marker chromosomes only,
but no MK.
Aberrations in chromosome 12p were counted as abnormality
independent of the breakpoint or other aberrations. For this analysis, a
subgroup of patients was retrospectively deﬁned as having a very high risk
of relapse depending on the following cytogenetic criteria: inv(3)
(q21q26.2)/t(3;3)(q21;q26.2), t(6;9)(p23;q34), t(7;12)(q36;p13), t(5;11)(q35.3;
p15), t(9;22)(q34;q11), monosomy 7, aberrations in chromosome 12p, and
MLL-rearrangement due to t(4;11)(q21;q23), t(6;11)(q27;q23) or t(10;11)
(p12;q23).
Statistical analyses
Statistical analyses were performed with SAS version 9.03 (SAS Institute,
Cary, NC, USA). The median follow-up was 5.6 years. The Kaplan–Meier
method was applied to estimate probabilities of survival. EFS and OS were
compared with the log rank test. Construction of the cumulative incidence
of relapse (CIR), the cumulative incidence of nonresponse and death in
continuous complete remission (CCR) was based on the Kalbﬂeisch and
Prentice method.36 Gray’s method was used to compare cumulative
incidences. The Cox proportional hazards model was used for multivariate
analysis of outcomes or nonresponse and relapse. The following
parameters were used for multivariate analysis: cytogenetic standard risk
group, MK, monosomy 7, isolated trisomy 8, FLT3 mutation, other
genetically deﬁned high-risk factors, bone marrow day 15 and HSCT.
Proportions were compared between groups using the Chi-square or
Fisher’s exact test. If not further speciﬁed, we refer to the remaining
patients (others than patients of the analyzed subgroup) as comparator
group. For further analysis and discussion, published data from study AML-
BFM 98 were included.2 The database lock for this analysis was set at ﬁrst
of July 2016.
RESULTS
Prognoses among cytogenetic subgroups in the AML-BFM 04
study
The 5-year EFS of all study patients with cytogenetic data (n= 701)
was 55 ± 2% compared to 49 ± 2% in our previous study (n= 457,
AML-BFM 98).2 For detailed information regarding incidences,
outcomes and initial data of cytogenetic aberrations see
Supplementary Tables 1 and 2. If not otherwise speciﬁed, the
following outcome data always refer to the remaining patients
excluding patients with t(15;17) (others than patients of the
analyzed subgroup) as comparator group.
Patients with favorable cytogenetic aberrations showed an
excellent response to induction therapy with CR rates of 95%
(t(8;21)(q22;q22)/RUNX1-RUNX1T1) and 97% (inv(16)(p13.1q22)/
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CBFB-MYH11) and signiﬁcantly better survival rates (EFS 65 ± 6%,
P= 0.028 and EFS 77 ± 6%, Po0.0001) compared to the remaining
patients of the study (Supplementary Table 2). However, the EFS
of patients with t(8;21) was signiﬁcantly lower compared to that of
AML-BFM 98 (65 ± 6% vs 84 ± 5%, P= 0.021) due to a temporary
change in the reinduction therapy without high-dose cytarabine
and mitoxantrone (HAM) in study AML-BFM 04 as described by
Creutzig et al. (Supplementary Table 2).37 In contrast to our
previous study, the prognosis in patients with an MLL-rearrange-
ment was not signiﬁcantly inferior to that of the remaining cohort
(EFS 54 ± 4%, P= 0.91) and was signiﬁcantly better than that in the
AML-BFM 98 cohort (EFS 54± 4% vs 34 ± 5%, P= 0.0063;
Supplementary Tables 2 and 5). Patients with aberrations of
chromosome 7q had a worse prognosis (EFS 21 ± 13%, P= 0.0073)
than those in the AML-BFM 98 study, but only in terms of EFS
(Supplementary Table 2).
This study conﬁrmed the poor prognosis in terms of EFS and CIR
associated with aberrations in 12p (EFS 24 ± 9%, P= 0.0011; CIR
53± 11%, P= 0.01; Supplementary Table 2).
In addition, patients with trisomy 8 had a signiﬁcantly poorer
outcome compared to the other patients of the study, but only
if this aberration was exclusive (EFS 25± 11%, P= 0.0091 and
OS 42± 13, P= 0.011). Four patients were nonresponders (25%),
and seven patients relapsed (44%) (Supplementary Tables 1
and 2). On multivariate analysis, isolated trisomy 8 showed a
hazard ratio (HR) of 1.98 for EFS (95% conﬁdence interval (CI) 0.99–
3.97, P= 0.053; Table 3).
Patients with the retrospectively analyzed high-risk factors
according to genotype (see cytogenetic deﬁnition) (13%) had a
signiﬁcantly lower survival (EFS 33 ± 4%, Po0.0001 and OS
57± 6%, P= 0.0003) compared to other patients (Supplementary
Table 2). CR was achieved by 75% of these patients. The predicted
poor outcomes were conﬁrmed retrospectively in the AML-BFM 98
data (EFS 22± 7%).
For the following analyses, outcome results of all patients with
cytogenetic data were used to evaluate the novel high-risk criteria
in detail. If not otherwise speciﬁed, the following sections always
refer to the remaining patients (others than patients of the
analyzed subgroup, excluding patients with t(15;17) as
comparator group.
Prognosis with novel cytogenetic high-risk criteria in the study
AML-BFM 04
A high level of complexity based on overlapping subgroups (MK+,
CK+ and HK+) was detected in our cohort (see Figure 1a; initial
data in Table 1). Several patients met the deﬁnitions of more than
one subgroup, and three patients fulﬁlled the criteria for all three
deﬁnitions. Of these three patients, two experienced relapse, and
one is in CCR.
Prognosis with monosomal karyotype
Twenty-two patients (3%) met the criteria for MK+ as deﬁned by
Breems et al. (for details on the distribution of monosomies in
patients with MK, see Figure 2a and Supplementary Table 6). MK+
patients were younger (median age, 3.9 years) than the
comparator group and showed signiﬁcantly reduced EFS and
OS compared to other patients (23 ± 9%, P= 0.0003 and
35 ± 10%, Po0.0001, respectively; Tables 1 and 2, Figures 2b
and c). Seventy-seven percent of MK+ patients achieved CR after
induction therapy, but the CIR was high (46 ± 11%, P= 0.08).
Multivariate analysis identiﬁed MK+ as an independent high-risk
factor (EFS: HR 2.44, 95% CI 1.27–4.69, P= 0.007 and nonresponse
or relapse: HR 2.56, 95% CI 1.28–5.09, P= 0.007; Table 3).
Fourteen MK+ patients were analyzed for FLT3 mutations, and
no such mutation was detected.
Monosomal karyotype and monosomy 7
Four MK+ patients also were missing chromosome 7 (Table 1).
After excluding these patients, the remaining patients (labeled
MK+ no − 7) still experienced a poor outcome (EFS 28 ± 11%,
P= 0.0081; Table 2). Although 89% of them achieved CR, their risk
of relapse was high (CIR 50 ± 13%, P= 0.03; Table 2). Only two
patients had an isolated monosomy 7. Both patients died after
Figure 1. (a) Schematic presentation of overlapping groups of
patients with AML according to their cytogenetically deﬁned
karyotype. (b) Event-free survival of patients with complex (CK)
and monosomal karyotype (MK). (c) EFS for patients with MK and
hypodiploid karyotype (HK).
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nonresponse. Overall, the seven patients with monosomy 7 showed
the expected adverse outcome (EFS 14±13%, P=0.0018), with a
poor response to therapy (CR 29%, Po0.001) compared to all other
patients (Supplementary Table 2).
Multivariate analysis of EFS, established to distinguish MK+ no − 7
patients and those with monosomy 7, identiﬁed monosomy 7 as
independent prognostic factors for poor survival (monosomy 7:
HR 4.53; 95% CI 1.43–14.35; P= 0.01 and MK+ no − 7: HR 2.08, 95% CI
0.96–4.48, P= 0.062; Supplementary Table 3). This was further
conﬁrmed by Cox regression analysis of the incidence of
nonresponse and relapse (Supplementary Table 3).
Monosomal and complex karyotype
Twelve patients met the criteria for MK+/CK+ and had a very poor
prognosis (EFS 25± 13%, P= 0.024 and OS 25 ± 13%, P= 0.0001)
compared to that of other patients (Table 2). The remaining MK+
patients without a CK (MK+/CK−) had a similarly unfavorable
prognosis (EFS 20 ± 13%, P= 0.0029; Figure 1b and Table 2). The
presence of CK did not change outcome of MK patients
signiﬁcantly (EFS MK+/CK− vs MK+/CK+, P= 0.58). Also, the poor
outcome of patients with MK was not dependent on the presence
of complex aberrations according to Grimwade et al.
(Supplementary Table 4).
Monosomal and hypodiploid karyotype
Ten patients who fulﬁlled the criteria for both MK and HK showed
very poor EFS (10 ± 10%, Po0.0001; Figure 1c) and a signiﬁcantly
increased CIR (70 ± 17%, Po0.0001; Table 2) compared to other
patients. The event-free survival of MK+/HK− vs MK+/HK+ was not
signiﬁcantly different (P= 0.19). HK+ independent of MK+ did not
signiﬁcantly affect patients’ outcome (EFS 44 ± 8%, P= 0.30;
Table 2).
Monosomal and marker chromosomes
Ten out of 22 patients with MK showed the presence of a marker
chromosome, including one ring chromosome (45%). Patient with
MK without any involvement of a marker chromosome still
showed a very poor survival (EFS 25 ± 13%, P= 0.007 and OS
40± 15, P= 0.011; Table 2). The event-free survival of patients with
presence of a marker chromosome but no MK was not
signiﬁcantly different compared to the remaining patients of the
comparator group (EFS 45 ± 10%, P= 0.30 and OS 62 ± 10%,
P= 0.44; Table 2).
Prognosis with complex karyotype
Fifty-nine patients (9%) were CK+ (see Table 1 for initial data), and
only 3 of the 32 analyzed CK+ patients had an additional FLT3
mutation. Of note, no patient with CK+ showed a monosomy 7.
Survival in CK+ patients did not differ from that of other patients
(EFS 43 ± 7%, P= 0.099 and OS 58 ± 7%, P= 0.082; Table 2). After
exclusion of patients with additional criteria for MK+, the
remaining patients had an EFS of 47 ± 8% (P= 0.46) and OS of
68 ± 7% (P= 0.91; Table 2). An additional analysis showed that
complex karyotypes with 2–3, 4–5 or45 aberrations according to
the deﬁnition of Grimwade et al. did not show signiﬁcant changes
in EFS, whereas patients with 45 aberrations had a reduced OS
(P= 0.0008) independent of the presence of MK (Supplementary
Table 4).
Prognosis with hypodiploid karyotype
A HK (n= 37, 6%) was frequently detected in FAB M2 patients
(54%) (Table 1). HK+ associated with t(8;21) was characterized by
loss of sex chromosomes (n= 21, 57%). Overall, the outcomes
among HK+ patients did not differ from those of other patients
(EFS 44 ± 8%, P = 0.30; Table 2). As described the presence of MK
signiﬁcantly inﬂuenced patient’s outcome (EFS HK+/MK− vs HK+/
MK+, P = 0.04). In patients with t(8;21), concurrent HK did not
have a signiﬁcant impact on prognosis (EFS 70 ± 10% (n= 21 HK+)
vs 63 ± 7% (n = 55 HK−), P= 0.5) However, after exclusion of
patients with t(8;21), the remaining HK+ patients had a very poor
prognosis (n= 16, EFS 9 ± 8%, Po0.0001; Table 2). Six of these
patients did not have concurrent MK+ and all had an event
(EFS = 0).
Table 1. Initial data for monosomal, complex and hypodiploid karyotypes
With
cytogenetic
data
Monosomal
karyotype
(MK+)
MK+ excluding
− 7
MK+ and
complex
karyotype
(MK+/CK+)
MK+ and
hypodiploid
karyotype
(MK+/HK+)
Complex
karyotype
Hypodiploid
karyotype
n % n % n % n % n % n % n %
Patients 642 100 22 100 18 100 12 100 10 100 59 100 37 100
Age (median, years) 9 — 3.9 — 3.2 — 3.9 — 5.2 — 3.7 — 10 —
Male 334 52 6 27 3 17 3 25 3 30 30 51 20 54
Female 308 48 16 73 15 83 9 75 7 70 29 49 17 46
M0 27 4 3 14 1 6 1 8 3 30 8 14 4 11
M1/M2 247 38 6 27 5 28 4 33 2 20 20 34 27 73
M4 Eo+ 64 10 — — — — — — — — — — — —
M4Eo− /M5 239 37 8 36 7 39 2 17 4 40 14 24 5 13
M6 13 2 1 5 1 6 1 8 — 4 7 — —
M7 43 7 4 18 4 22 4 33 1 10 13 22 1 3
Non-classiﬁed 9 1 — — — — — — — — — — —
CNS+ 85 13 2 9 1 6 1 8 — — 7 12 1 3
Organ+ 170 26 7 32 5 28 2 17 3 30 17 29 6 16
WBC (median, 103/μl) 19 800 — 9900 — 12 590 — 9900 — 11 390 — 11 370 — 11 020 —
Hb (median, g/dl) 8.1 — 7.4 — 7.7 — 7.9 — 7.8 — 8.1 — 7.1 —
BM blasts day 15 ⩾ 5% 109 17 6 27 5 28 3 25 4 40 17 29 8 22
Abbreviations: BM, bone marrow; CNS+, with CNS involvement; Eo− , without atypical eosinophils; Eo+, with atypical eosinophils; Hb, hemoglobin; Organ+,
extramedullary disease apart from spleen and liver; WBC, white blood cell count.
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DISCUSSION
Conﬂicting data from trial groups regarding the prognostic value
of several cytogenetic and molecular aberrations have prevented
the establishment of uniform risk-adapted therapy in pediatric
AML. Accordingly, the prognostic signiﬁcance of the isolated or
combined occurrence of several factors such as MK, CK, HK and
trisomy 8 has remained largely unclear. Our aim was to elucidate
the role of potentially unfavorable risk factors in a large cohort of
pediatric AML patients. So far, no pediatric study has included a
clearly deﬁned MK as a high-risk factor. In adults with AML, MK is a
well-recognized adverse prognostic factor based on several large
studies demonstrating the extremely poor prognosis of these
patients.8,10,12 These studies further showed an association of MK
with multidrug resistance activity and reported conﬂicting results
regarding the possible beneﬁt of HSCT.9,38–41 Therefore, the best
risk-adapted therapeutic approach for these high-risk patients is
still under debate.
In one pediatric study, Manola et al. did not detect signiﬁcant
differences in the initial response to induction therapy in 15 out
of 244 (6%) patients with MK. However, small patient numbers
and a high percentage of patients categorized as having AML
with MDS-related features limited their study.14 Notably, in
childhood MDS, MK is associated with a heterogeneous
prognosis,42 which is in accordance with adult studies and thus
creates doubt concerning the independent prognostic value of
this karyotype in MDS.43–45
Here, in a much larger cohort of pediatric AML patients we
identiﬁed MK as a strong and independent predictor of high-risk
AML in univariate and multivariate analysis that does not require
involvement of chromosome 7. These patients showed an
extremely poor EFS and OS. Consistent with studies in adults,
we did not detect any FLT3 mutations in our MK+ patients, but
also identiﬁed a relevant overlap between MK and CK.46,47 We
included the presence of a marker chromosome that may be a
result of pronounced clonal instability, even though a monos-
omy combined with a marker chromosome often may not be a
complete monosomy. However, we excluded patients with only
one autosomal monosomy combined with a marker chromo-
some, but no additional aberration as described by Breems et al.8
As described before in patients with MDS, 45% of our patients
with MK showed the presence of a marker chromosome, which is
in a range with Schanz et al.45 Of note, an additional analysis
with exclusion of patients with any involvement of a marker
chromosome still showed a very poor survival (EFS P= 0.007 and
OS P = 0.011).8 The prognosis did not differ compared to the
other deﬁnitions of MK in this cohort. The EFS of patients with
presence of a marker chromosome but no MK was not
signiﬁcantly different compared to the remaining patients of
the comparator group.
Patients with a CK only and no MK did not experience outcomes
worse than the remaining patients. However, the better results of
patients with CK in the current study must be interpreted with
caution due to changes in therapy schedules. In the study AML-
BFM 04, 11 CK+ patients received HCST in 1st CR, whereas in the
trial AML-BFM 98, only one patient underwent transplantation.
This might indicate treatment-dependent variability of this ﬁnding
and should be considered in the establishment of further risk
deﬁnitions.
Of note, a small subgroup of patients that fulﬁlled the deﬁnition
of MK has been described in case reports: monosomy 7 combined
with ectopic virus integration site-1 aberrations and/or abnorm-
alities in chromosome 3q26/inv3. This karyotype seems to confer a
very poor prognosis and may be associated with diabetes
insipidus.48–50 One patient in our cohort had this karyotype. He
showed an exceedingly complicated course, never achieving CR
and dying only 6 months after diagnosis.
In our study cohort, we conﬁrmed the incidence (6%) of
hypodiploidy in pediatric AML and its association with t(8;21)
and AML FAB M2 as reported by the pediatric Nordic Society of
Pediatric Hematology and Oncology (NOPHO) study (incidence
8%).15 We could not verify a male predominance or an
unfavorable overall prognosis for these patients (EFS 44 ± 8%,
P = 0.3). However, the small subgroup of patients who fulﬁlled
criteria for MK and HK or HK without concurrent t(8;21)
were identiﬁed as having a very high risk of relapse and poor
survival.
Figure 2. (a) Distribution of monosomies in patients with mono-
somal karyotype. n=number of monosomies; MK, monosomal
karyotype. (b) EFS for patients with MK compared to patients with
standard risk (SR), intermediate (MR) and other high-risk factors.
(c) OS for patients with MK compared to patients with SR,
intermediate risk and other high-risk factors. Deﬁnition of inter-
mediate risk according to the AML-BFM 2012 protocol, deﬁned as no
favorable or high-risk criteria.
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The prognostic signiﬁcance of trisomy 8 in pediatric AML
remains unclear. In adult AML, controversial studies have under-
lined the heterogeneity of this cytogenetic group.48–50 In our
cohort, trisomy 8 was associated with very poor survival, but only
if detected as the only cytogenetic aberration. Notably, 4 of 16
patients with trisomy 8 showed FLT3 mutations. Owing to the
observed heterogeneity and conﬂicting data in adult AML, more
pediatric studies are required to determine the prognostic impact
of trisomy 8 or hypodiploidy (without t(8;21)).
In conclusion, we identiﬁed MK as a strong prognostic factor
for poor outcome in pediatric AML. Isolated trisomy 8 or HK
without t(8;21) are potentially predicting a dismal prognosis.
In contrast, CK alone or HK did not seem to confer an
adverse prognosis. Our current study protocol (AML-BFM
2012) includes cytogenetic risk factors for stratiﬁcation (stan-
dard-, intermediate- and high-risk), and HSCT in 1st CR is
recommended in cytogenetically and response-deﬁned high-
risk patients. Validation of these ﬁndings in independent
pediatric patient cohorts will indicate that MK+ should be
included as an important, novel adverse parameter in the list of
high-risk criteria.
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Table 2. Treatment results in patients with monosomal, complex and hypodiploid karyotypes
Patients CR SR HR 5-years
pEFS
P (Log rank)a 5-year
pOS
P (Log rank)a CIR P (Gray)a
n % n % % % % SE % SE % SE
Total no. of patients with cytogenetic data
(excluding t(15;17))
642 100 558 87 29 71 52 2 70 2 32 2
Monosomal karyotypeb (MK+) 22 3 17 77 — 100 23 9 0.0003 35 10 o0.0001 46 11 0.08
monosomal karyotype excluding marker
chromosomes
12 2 8 67 — 100 25 13 0.007 40 15 0.011 42 16 0.29
monosomal karyotypeb excluding − 7 18 3 16 89 — 100 28 11 0.0081 38 12 0.001 50 13 0.03
MK+ and complex karyotype (MK+/CK+) 12 2 10 83 — 100 25 13 0.024 25 13 0.0001 42 16 0.41
MK+ without complex karyotype (MK+/CK−) 10 2 7 70 — 100 20 13 0.0029 50 16 0.084 50 18 0.07
MK+ and hypodiploid karyotype (MK+/HK+) 10 2 8 80 — 100 10 10 o0.0001 40 16 0.0096 70 17 o0.0001
MK+ without hypodiploid karyotype
(MK+/HK−)
12 2 9 75 — 100 33 14 0.12 30 14 0.0023 25 14 0.57
Marker chromsomes without MK 26 4 24 92 22 73 45 10 0.30 62 10 0.44 44 10 0.08
Hypodiploid karyotypec (HK+) 37 6 32 87 51 49 44 8 0.30 64 8 0.38 36 8 0.44
without t(8;21) 16 2 13 81 12.5 87.5 9 8 o0.0001 38 12 0.0002 56 13 0.003
without monosomal karyotype (HK+/MK−) 27 4 24 89 70 30 57 10 0.50 73 9 0.70 23 9 0.33
Complex karyotyped (CK+) 59 9 54 92 12 88 43 7 0.099 58 7 0.082 44 7 0.02
complex karyotyped without monosomal
karyotyped (CK+/MK−)
47 7 44 94 15 85 47 8 0.46 68 7 0.91 44 8 0.03
Abbreviations: CIR, cumulative incidence of relapse; CR, complete remission; HR, high-risk treatment of AML-BFM 2004; pEFS, probability of event-free survival;
OS, overall survival; SE, standard error; SR, standard risk treatment of AML-BFM 2004. aP-value indicates whether the differences are signiﬁcant in comparison
to other patients with cytogenetic data (excluding patients with t(15;17)). bTwo or more autosomal monosomies or one autosomal monosomy with at least
one structural abnormality, according to Breems et al. No favorable cytogenetics (t(15;17)(q22;q21); t(8;21)(q22;q22); inv(16)(p13q22)/t(16;16)(p13;q22)). co46
chromosomes. dThree or more aberrations, at least one structural aberration; without favorable genetics; without MLL-rearrangement.
Table 3. Results of multivariate analysis including MK
EFS NR/relapse
HR 95% CI P (Chi) HR 95% CI P (Chi)
LL UL LL UL
Cytogen. SR 0.56 0.38 0.81 0.003 0.60 0.41 0.89 0.011
MK 2.44 1.27 4.69 0.007 2.56 1.28 5.09 0.007
Isolated trisomy 8 1.98 0.99 3.97 0.053 2.03 0.97 4.23 0.060
FLT3 mutation 2.14 1.47 3.12 o0.001 2.25 1.52 3.35 o0.001
Other gen. high-risk factors 1.47 0.91 2.38 0.111 1.59 0.97 2.60 0.064
BM day 15 2.28 1.67 3.13 o0.001 2.51 1.81 3.48 o0.001
HSCT 0.28 0.13 0.58 0.001 0.18 0.07 0.44 o0.001
Abbreviations: BM, bone marrow; CI, conﬁdence interval; HR, hazard ratio; HSCT, hematopoietic stem cell transplantation; MK, monosomal karyotype; NR,
nonresponse; EFS, event-free survival; SR, standard risk; other genetically deﬁned high-risk factors including inv(3)/t(3;3)(q21q26.2), t(6;9)(p23;q34), t(7;12)(q36;
p13), t(4;11)(q21;q23), t(5;11)(q35.3;p15), t(6;11)(q27;q23), t(10;11)(p12;q23), t(9;22)(q34;q11), aberrations in 12p.
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